Dr. Wen Zhou received his MD from Peking University, Beijing, China (2001-2006). He got his Ph.D. from the University of Miami, FL in 2014, where he studied how ubiquitin SCF ligases function as dual-role co-activators of ERα to drive ERα target gene expression and receptor proteolysis. His work has provided a novel rationale for the investigation of ubiquitin E3 ligase inhibitors together with anti-estrogens for breast cancer therapy. He was further trained in the Sylvester Comprehensive Cancer Center with Dr. Joyce M. Slingerland and the Columbia University with Dr. Carol Prives as postdoctoral fellow and research scientist. During his postdoc training course, he was enthusiasm in breast cancer stemness and p53 biology.
He is an Associate Faculty Member of Faculty of 1000 - "Women's Health" Faculty. He is in the editorial boards of several Nature Publishing Group journals, including Frontiers in Endocrinology and Frontiers in Oncology. He is also a CNKI oversea expert for Tsinghua Tongfang Inc., China. He has published a number of highly cited articles, including Nature Reviews Cancer, Oncogene, Mol Cell Biol, and J Biol Chem. His research projects have been generously funded by US Department of Defense.
Dr. Wen Zhou's research interests include
